Clinical & Translational Oncology最新文献

{"title":"Clinical metric of tumor mutational burden depicts colorectal cancer patients at the extremes.","authors":"Ming Zheng","doi":"10.1007/s12094-025-03873-6","DOIUrl":"10.1007/s12094-025-03873-6","url":null,"abstract":"<p><strong>Purpose: </strong>Rare cases of colorectal cancer patients with exceptionally good or poor prognosis often remain overlooked, limiting insights into prognostic factors and underlying mechanisms.</p><p><strong>Methods: </strong>This study developed an analytical framework to investigate cancer patients at the extremes using tumor mutational burden (TMB). By analyzing data from 1277 colorectal cancer patients who did not receive immunotherapy, this analysis assessed how patient survival varies with a broad range of TMB levels.</p><p><strong>Results: </strong>Among patients with TMB ≤ 10 mutations per megabase (mut/Mb), increasing TMB was associated with worse survival outcomes. In contrast, patients with TMB > 10 mut/Mb showed  increasingly improved survival. Notably, a small subgroup (3.83%) with TMB > 60 mut/Mb had significantly better survival outcomes.</p><p><strong>Conclusions: </strong>These findings highlight TMB's dual role in colorectal cancer progression. This study suggests that atypical patients can coexist within the same \"disease continuum\" with typical patients, under the universal context unified by a shared cancer hallmark. TMB provides a useful biomarker for identifying these extremes, offering a clinical metric to better predict patient outcomes and personalize treatment strategies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3550-3554"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic predisposition to polyposis syndromes.","authors":"Natalia García-Simón, Fátima Valentín, Atocha Romero","doi":"10.1007/s12094-024-03825-6","DOIUrl":"10.1007/s12094-024-03825-6","url":null,"abstract":"<p><p>Hereditary polyposis syndromes are significant contributors to colorectal cancer (CRC). These syndromes are characterized by the development of various types and numbers of polyps, distinct inheritance patterns, and extracolonic manifestations. This review explores these syndromes with a focus on their genetic characteristics. Advances in diagnostics, particularly the identification of pathogenic germline variants through massive sequencing technologies, have enhanced our understanding of the genetic alterations associated with polyp formation and CRC risk. Identifying pathogenic variants beyond traditional diagnostic criteria improves the management and surveillance of these syndromes. Genetic diagnosis not only refines patient treatment and surveillance, but also informs relatives of potential risks, enabling appropriate management. However, challenges persist in determining the pathogenicity of newly discovered mutations due to their low prevalence. This review covers hereditary polyposis syndromes, from well-established to newly recognized types, providing insights into their genetic landscapes and highlighting the need for tailored surveillance based on genotype.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3272-3284"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142967467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the benefits of immunotherapy in metastatic cervical cancer: an observational retrospective analysis.","authors":"Ana Isabel Martín-Quesada, Lina Pérez-Mendez, Natalia Dolores Pérez-Rodríguez","doi":"10.1007/s12094-025-03852-x","DOIUrl":"10.1007/s12094-025-03852-x","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is the fourth most commonly diagnosed cancer and the fourth leading cause of cancer-related death in women globally. Recent advances in immunotherapy have demonstrated promising results. This study analyses the real-world impact of adding immunotherapy for patients with stage IV cervical carcinoma.</p><p><strong>Material and methods: </strong>This longitudinal retrospective observational study included patients with stage IV cervical carcinoma in the first metastatic setting treated between 2010 and 2023 at the University Hospital Nuestra Señora de Candelaria in Tenerife, Spain. To evaluate the primary objective, patients were divided into two groups depending on whether they had received immunotherapy with pembrolizumab or not. The primary endpoint was 12-month progression-free survival in patients receiving immunotherapy compared to those not receiving it.</p><p><strong>Results: </strong>A total of 56 patients were analyzed, of whom 31 were tested for PD-L1. Among those tested, 25 patients (84%) were PD-L1 positive, and 18 of them (72%) received immunotherapy. The objective response rate was significantly higher, being 94% in the group that received immunotherapy, compared to 32% in the group that did not (p < 0.001). At 12 months, the cumulative probability of progression-free survival was estimated at 94.4% for the immunotherapy group versus 59.7% in the non-immunotherapy group (p = 0.009), with a hazard ratio of 0.116 (CI_95%: 0015 - 0.883; p = 0.038). Immunotherapy alone or combined with bevacizumab showed similar progression-free survival probabilities. However, these outcomes were significantly different when compared to patients who received neither therapy (p < 0.001).</p><p><strong>Conclusions: </strong>Our findings confirm that immunotherapy significantly improves progression-free survival and objective response rates in metastatic cervical carcinoma, aligning with the results from the KEYNOTE-826 trial. The implementation of PD-L1 testing and the addition of immunotherapy whenever possible are challenges to be achieved in clinical practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3535-3542"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.","authors":"Ignacio Peláez, Martín Lázaro-Quintela, Daniel Pérez-Fentes, Emilio Esteban-González, Enrique Gallardo, Carlos Álvarez-Fernández, Pablo Álvarez Rodríguez, Urbano Anido-Herranz, Cristina Azpitarte Raposeiras, Ángel Maximino Castro-Iglesias, Ovidio Fernández Calvo, Natalia Fernández Núñez, Alicia Folgar-Torres, Carme García Lorenzo, Aránzazu González-Del-Alba, María José Méndez-Vidal, Aurea Molina Díaz, Ignacio Rodríguez Gómez, Sergio Vázquez-Estévez","doi":"10.1007/s12094-025-03850-z","DOIUrl":"10.1007/s12094-025-03850-z","url":null,"abstract":"<p><p>Prostate, bladder and kidney neoplasms are among the most prevalent genitourinary (GU) cancers worldwide. Significant therapeutic advancements in recent years have substantially improved patient outcomes. In response to this rapid progress, the Santiago de Compostela Health Research Institute (IDIS) has organized the annual 'Cambados Consensus Forum on Genitourinary Tumors' (Pontevedra, Spain) since 2018. This 2-day multidisciplinary meeting gathers Spanish medical oncologists, radiation oncologists, urologists, and hospital pharmacists to present and discuss the latest evidence in the field, merging from international congresses or journal publications. This review provides an overview of the most recent evidence regarding therapeutic advances in prostate cancer, renal cell carcinoma, and bladder cancer presented at the 2024 meeting (October), with a special focus on practice-changing innovations.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3307-3324"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025).","authors":"Teresa Macarulla, Jorge Adeva, Maria Teresa Cano Osuna, Ana Ruiz Casado, Ana María Jiménez Gordo, Angela Lamarca, Ana María López Muñoz, Roberto Antonio Pazo Cid, Tamara Saurí, Javier Gallego Plazas","doi":"10.1007/s12094-025-03916-y","DOIUrl":"10.1007/s12094-025-03916-y","url":null,"abstract":"<p><p>Biliary tract cancers (BTC) are aggressive and fatal. Early recognition of symptoms and proper diagnostic work up allow for precise histopathological and molecular classification as well as accurate evaluation of the extent of disease. Surgery is the only potentially curative therapy in localized stages; however, disease recurrence is common and adjuvant chemotherapy appears to improve survival. Upfront systemic chemotherapy with immunotherapy is the treatment of choice in unresectable locally-advanced and metastatic disease. Inroads made in understanding its molecular biology has enabled new therapeutic targets to be identified with current indications and encouraging results that could further improve BTC patients' survival and quality of life.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3293-3306"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse/progressive disease.","authors":"Blanca Martínez de Las Heras, Pedro M Rubio-Aparicio, Alba Rubio-San-Simón, Lucas Moreno, Paula Mazorra, Ricardo López Almaraz, Mercedes Llempén López, Julia Balaguer Guill, Vanessa Segura, Mar Bermúdez, Irene Jiménez, Désirée Ramal, Adela Cañete","doi":"10.1007/s12094-025-03853-w","DOIUrl":"10.1007/s12094-025-03853-w","url":null,"abstract":"<p><strong>Purpose: </strong>Outcome for children with refractory and relapse/progressive high-risk neuroblastoma (HR-NB) remains poor, without an internationally agreed standard second-line approach. Heterogeneity in patients' disease and treatment strategies challenges clinical management. The survival rate for patients with resistant disease does not exceed 20% at 5 years. The study's aim was to analyze refractory and progressive HR-NB patients in a real-world setting to evaluate current clinical practices and optimize future approaches.</p><p><strong>Methods: </strong>Data from patients diagnosed with refractory and relapse/progressive (R/R-P) HR-NB between January 2019 and December 2021 at six of the major Spanish neuroblastoma treating hospitals were collected and analyzed.</p><p><strong>Results: </strong>A total of 67 episodes of R/R-P HR-NB were included. Treatments applied included chemotherapy (97%), immunotherapy (48%), consolidation (21%), local treatment (surgery and/or radiotherapy) (45%) and maintenance (16%), and were administered within a clinical trial (CT) in 34% of the episodes. Biopsy was performed in 37% of the tumors and 30% were profiled. Event-free survival (EFS) in our cohort was 20.9% and overall survival (OS) 32%. Significant survival advantage (in both OS and EFS) was observed in refractory episodes compared to relapse/progressive, in first events compared to successive, and when response or disease stabilization was achieved. MYCN status, presence of lymph node metastases, use of irinotecan or topotecan, and radiotherapy were also univariate predictors of OS.</p><p><strong>Conclusions: </strong>Treatment of refractory and relapse/progressive HR-NB is highly heterogeneous. We confirm a poor outcome, although certain epidemiological and treatment-related factors have prognostic value. Molecular profiling and inclusion in CTs should be improved.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3421-3431"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A PET/CT-based 3D deep learning model for predicting spread through air spaces in stage I lung adenocarcinoma.","authors":"Cheng Zheng, Yujie Cai, Jiangfeng Miao, BingShu Zheng, Yan Gao, Chen Shen, ShanLei Bao, ZhongHua Tan, ChunFeng Sun","doi":"10.1007/s12094-025-03870-9","DOIUrl":"10.1007/s12094-025-03870-9","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluates a three-dimensional (3D) deep learning (DL) model based on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting the preoperative status of spread through air spaces (STAS) in patients with clinical stage I lung adenocarcinoma (LUAD).</p><p><strong>Methods: </strong>A retrospective analysis of 162 patients with stage I LUAD was conducted, splitting data into training and test sets (4:1). Six 3D DL models were developed, and the top-performing PET and CT models (ResNet50) were fused for optimal prediction. The model's clinical utility was assessed through a two-stage reader study.</p><p><strong>Results: </strong>The fused PET/CT model achieved an area under the curve (AUC) of 0.956 (95% CI 0.9230-0.9881) in the training set and 0.889 (95% CI 0.7624-1.0000) in the test set. Compared to three physicians, the model demonstrated superior sensitivity and specificity. After the artificial intelligence (AI) assistance's participation, the diagnostic accuracy of the physicians improved during their subsequent reading session.</p><p><strong>Conclusion: </strong>Our DL model demonstrates potential as a resource to aid physicians in predicting STAS status and preoperative treatment planning for stage I LUAD, though prospective validation is required.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3364-3374"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of failure after stereotactic body radiotherapy to non-spine bone metastases.","authors":"Héctor Pérez-Montero, Alicia Lozano, Rodolfo de Blas, Javier Hernández, Arantxa Mera, Ferrán Guedea, Arturo Navarro-Martín","doi":"10.1007/s12094-025-03878-1","DOIUrl":"10.1007/s12094-025-03878-1","url":null,"abstract":"<p><strong>Background and purpose: </strong>Stereotactic body radiotherapy (SBRT) has proven useful for non-spine bone metastases (NSBM). We analyzed local relapse rates and patterns of failure after NSBM-SBRT, contrasting our results with existing contouring guidelines.</p><p><strong>Materials and methods: </strong>We conducted a retrospective analysis of NSBM-SBRT treatments performed between 2013 and 2024 in a single institution. Clinical, pathologic, and treatment-related data were collected. Failure patterns were assessed based on imaging tests and categorized as in-field, marginal/out-of-field.</p><p><strong>Results: </strong>Among 119 NSBM-SBRT treatments in 85 patients, the most common primary tumors were prostate (36.1%) and breast cancer (24.4%). The coxal bone was the predominant metastatic site (52.9%). The median follow-up was 32.8 months. OS rates at 1, 2, and 3 years were 90.1%, 83.5%, and 75.8%, respectively. Twenty seven relapses were observed in the treated bone with a median recurrent tumor volume of 9.9 cm³ and a median time to recurrence of 15.1 months. Relapse-free survival in the treated bone was 89.4%, 78.5%, and 74.2% at 1, 2, and 3 years, respectively. Median recurrent tumor volume within the CTV was 50.6% and the median distance from the relapse center to the initial tumor was 11.4 mm.</p><p><strong>Conclusion: </strong>NSBM-SBRT provides effective local control with relapses often occurring near the initial tumor lesion. While adherence to existing contouring guidelines captures most scenarios, consideration of larger CTV expansions may be warranted in cases with poorer prognosis. Further studies are needed to identify risk factors for relapses outside the margins and optimize volume delineation in these scenarios.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3477-3484"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143505838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials.","authors":"Bilal Abu-Hussein, Amr Elrosasy, Haidy Samy, Ahmed Said Ali, Said Samir Alijla, Ahmad Naoras Bitar, Ibrahim Gamal","doi":"10.1007/s12094-025-03847-8","DOIUrl":"10.1007/s12094-025-03847-8","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains a leading cause of morbidity and mortality among women worldwide. According to the recent statistics by World Health Organization (WHO), it is the leading cause of death from cancer in women worldwide and it is the most frequently diagnosed cancer. This meta-analysis aims to systematically evaluate the efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.</p><p><strong>Method: </strong>We searched five databases; PubMed, Scopus, Science Direct, Web of Science, and Medline Plus. We included six studies. The applicable outcomes for meta-analysis about efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.</p><p><strong>Results: </strong>Six RCTs included in our meta-analysis found that Esketamine group had a statistically significant lower VAS score after 4 h, after 6 h, after 24 h, after 48 h; (MD = -1.54; 95% CI [-1.65, -1.42], P < 0.00001), (MD = -0.55; 95% CI [-0.66, -0.45], P < 0.00001), (MD = -0.75; 95% CI [-0.84, -0.66], P < 0.00001,), (MD = -0.26; 95% CI [-0.48, -0.03], P = 0.03) P < 0.00001), respectively.</p><p><strong>Conclusion: </strong>We conclude that S-ketamine is valuable for reducing pain and safe in patients undergoing modified radical mastectomy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3325-3339"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"USP14 targets FABP5-mediated ferroptosis to promote proliferation and cisplatin resistance of HNSCC.","authors":"Jiaxin Qian, Zitong Zhao, Liying Ma, Wensheng Liu, Yongmei Song","doi":"10.1007/s12094-025-03857-6","DOIUrl":"10.1007/s12094-025-03857-6","url":null,"abstract":"<p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC) ranks among the most lethal solid tumors in humans, with a five-year survival rate hovering around 50%. The limited understanding of its biological foundation has hindered the development of efficacious targeted therapeutics.</p><p><strong>Methods: </strong>TCGA database and immunohistochemistry were deployed to confirm the expression levels of ubiquitin specific protease 14 (USP14). CCK8 method was used to evaluate the influence of USP14 on cisplatin resistance. Further investigations into the role of USP14 were conducted through assessments of cell proliferation, colony formation, and Transwell assays. The impact of USP14 expression on ferroptosis was evaluated by measuring GSH/GSSG ratios, Fe²⁺ concentrations, and lipid peroxide levels. Co-IP was employed to verify the interaction between USP14 and FABP5.</p><p><strong>Results: </strong>Our analysis revealed that USP14 ranked among the most prominently upregulated deubiquitinases (DUBs) in tissue samples of HNSCC. Notably, aberrant USP14 expression was linked to tumorigenesis and the malignant evolution of HNSCC and further suggested a poor prognosis. In vitro experiment revealed that USP14 depletion markedly inhibited cell growth, cisplatin resistance, invasion and migration capabilities of HNSCC cells. Mechanically, USP14 inhibits FABP5 ubiquitination and degradation, thus positively modulating FABP5 expression. Subsequent analyses demonstrated that the loss of USP14 promoted ferroptosis in HNSCC cells. Finally, in vivo xenograft experiments confirmed that the USP14 small molecular antagonist IU1 could effectively attenuate cisplatin resistance in HNSCC.</p><p><strong>Conclusion: </strong>The results indicate that the USP14-FABP5 axis exerts oncogenic effects on HNSCC, providing a potential target for diagnosing and treating this type of malignancy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":"3485-3500"},"PeriodicalIF":2.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12259754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}